Zhitong Finance App News, Kang Fang Biotech (09926.HK) announced that the world's first independent bispecific antibody Edafang R (PD-1/VEGF) single drug compared with Pabolizil monotherapy was used for first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with positive PD-L1 expression (PD-L1 TPS ≥ 1%), randomized, double-blind, controlled, multicenter phase III clinical study (AK-112303/Harmoni-2), after an independent data monitoring committee (ID) MC) Evaluated Pre-set overall survival (OS) mid-term analysis results showed that the study reached a critical secondary OS endpoint and obtained positive results with statistically significant and clinical benefits. Detailed data on these results will be published in future international academic conferences and academic journals.

Zhitong Finance App News, Kang Fang Biotech (09926.HK) announced that the world's first independent bispecific antibody Edafang R (PD-1/VEGF) single drug compared with Pabolizil monotherapy was used for first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with positive PD-L1 expression (PD-L1 TPS ≥ 1%), randomized, double-blind, controlled, multicenter phase III clinical study (AK-112303/Harmoni-2), after an independent data monitoring committee (ID) MC) Evaluated Pre-set overall survival (OS) mid-term analysis results showed that the study reached a critical secondary OS endpoint and obtained positive results with statistically significant and clinical benefits. Detailed data on these results will be published in future international academic conferences and academic journals.